UBS O'Connor’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

UBS O'Connor’s Portfolio BIOSW Stock Details BIOSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-182,071	Closed	-$12.7K	–	668
2023 Q3	$12.7K	Hold	182,071	–	–	﹤0.01%	520
2023 Q2	$25.4K	Sell	182,071 -4,104	-2%	-$425	﹤0.01%	524
2023 Q1	$15.8K	Hold	186,175	–	–	﹤0.01%	570
2022 Q4	$9K	Sell	186,175 -1,822	-1%	-$93	﹤0.01%	707
2022 Q3	$27K	Sell	187,997 -18,820	-9%	-$2.1K	﹤0.01%	876
2022 Q2	$23K	Sell	206,817 -50,557	-20%	-$9.43K	﹤0.01%	902
2022 Q1	$58K	Buy	+257,374	New	+$66.8K	﹤0.01%	863

UBS O'Connor's BIOSW Position: Q4 2023 in Review

UBS O'Connor sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q4 2023, closing a stake of 182,071 shares — an estimated $12.7K sold.

UBS O'Connor first reported a position in BIOSW in Q1 2022 and held it in 7 quarters. The position peaked at $58K in Q1 2022. 0 funds tracked by Wall St. Rank hold BIOSW as of Q4 2023.

UBS O'Connor reported no remaining BioPlus Acquisition Corp. Warrants position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 182,071 BioPlus Acquisition Corp. Warrants shares in Q4 2023, an estimated $12.7K.
UBS O'Connor first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 7 quarters.
UBS O'Connor's BioPlus Acquisition Corp. Warrants position peaked at $58K in Q1 2022.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.